Browsing: Commentary
Guest commentary articles from industry experts from across the longevity and mortality markets. If you would like to submit an article for consideration for publishing by Longevity and Mortality Investor, please click here.
For life settlement markets, earlier diagnosis of chronic diseases may reduce projected life expectancy, thereby influencing the expected duration of premium payments and the timing of policy maturities.
How durational mortality curves, stochastic A/E analysis and independent audits can strengthen investor confidence and fund sustainability.
Fitch Ratings has a ‘neutral’ outlook for North American life insurers for 2026 despite a more challenging backdrop.
New policies that will fuel future trades in the life settlement market continue to be issued in healthy volumes, but in real terms, are slowly contracting.
In today’s rapidly evolving insurance landscape, the arrival of AI in Life and Health underwriting and claims workflows is no longer a distant possibility – it’s already a reality.
All in all, as counterparties for longevity and mortality risk investors, US life insurers remain strong.
The broader consequences of climate change are complex and far-reaching, with significant implications for human health, financial systems and the wider economy.
As with previous years, the US life insurance industry had a solid 2024 from a balance sheet perspective and continues to be healthy from a risk perspective.
The past four decades have brought revolutionary improvements in cancer care, transforming many forms of cancer from fatal diagnoses into chronic, manageable conditions.
Within the life settlement industry, the medical record review has long remained one of the most resource-intensive and time-consuming stages of the process but recent advancements in automation and artificial intelligence, however, are beginning to change this dynamic.